Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Nipro ( (JP:8086) ) is now available.
Nipro Corporation has decided to upgrade its existing Compensation Committee into a broader Nomination and Compensation Committee as a voluntary advisory body to the Board of Directors. The move, effective April 1, 2026, is designed to enhance fairness, transparency, and objectivity in director-related decisions and reinforce the company’s corporate governance framework.
The new committee will advise the board on the appointment and dismissal of directors, including representative and executive directors, as well as on directors’ compensation, maximum compensation limits, and succession planning. It will comprise at least three directors, with a majority being independent outside directors, underscoring Nipro’s effort to align with higher governance standards and strengthen oversight for shareholders and other stakeholders.
The most recent analyst rating on (JP:8086) stock is a Hold with a Yen1593.00 price target. To see the full list of analyst forecasts on Nipro stock, see the JP:8086 Stock Forecast page.
More about Nipro
Nipro Corporation is a Japan-based medical manufacturer listed on the Tokyo Stock Exchange Prime Market under securities code 8086. The company operates in the healthcare industry, focusing on medical devices and related products, and serves hospital, clinic, and broader healthcare markets in Japan and internationally.
Average Trading Volume: 532,854
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen254.7B
Learn more about 8086 stock on TipRanks’ Stock Analysis page.